Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 6

Emergence of new oral antithrombotics: a critical appraisal of their clinical potential

Authors Lassen MR, Laux V

Published 5 December 2008 Volume 2008:4(6) Pages 1373—1386


Review by Single anonymous peer review

Peer reviewer comments 4

Download Article [PDF] 

Michael Rud Lassen1, Volker Laux2

1Department of Orthopaedics and Clinical Trial Unit, Nordsjællands Hospital Hørsholm, University of Copenhagen, Hørsholm, Denmark; 2Thrombosis Research, Bayer Schering Pharma, Wuppertal, Germany

Abstract: In Western countries, venous thromboembolism (VTE) is a widespread and serious disorder, with hospital admission rates that appear to be increasing. Current anticoagulant therapies available for the prevention and treatment of VTE have several drawbacks that make them either difficult to manage effectively, due to a need for careful monitoring to control coagulation, or, in the case of parenterally administered agents, inconvenient for long-term use. To address some of these issues, new anticoagulants are in clinical development that can be orally administered and directly target specific factors in the coagulation cascade. This article reviews the rationale behind development of these novel agents and provides a critical appraisal of their clinical potential. In addition, the impact that the introduction of such agents into clinical practice would have is discussed from the patient perspective.

Keywords: antithrombotic agents, venous thromboembolism, Factor Xa, thrombin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]